Lantern Pharma Inc. (NASDAQ:LTRN)’s investigational drug LP-184 has achieved a major milestone in the fight against pediatric brain cancer, following independent validation by Johns Hopkins University ...

CHARLOTTESVILLE, Va., Sept. 4, 2025 /PRNewswire/ -- RIVANNA®, developers of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) ...

Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. This ...

LP-184 is the first of Lantern’s drug candidates developed by leveraging Lantern’s AI platform, RADR® US FDA previously granted LP-184 Rare Pediatric Disease Designation and Orphan Drug Designation ...

Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trial The data ...

DALLAS - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotech company with a current market capitalization of approximately $31 million, has unveiled promising preclinical data for its drug ...

However, traditional LP procedures can often be challenging, leading to traumatic lumbar punctures (TLPs)—procedures in which cerebrospinal fluid becomes contaminated with blood. TLPs, which affect up ...